lactate dehydrogenase A like 6E, pseudogeneGenealiases: []
Q-omics provides the consensus-scored LDHAL6EP profile across patient tissues and cancer cell-line models. LDHAL6EP expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, LDHAL6EP is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, LDHAL6EP RNA expression shows 13,662 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight THCA, COAD, and PDAC as cancer lineages where LDHAL6EP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LDHAL6EP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LDHAL6EP survival associations across molecular data types. LDHAL6EP RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LDHAL6EP RNA expression–survival associations across cancer types. High LDHAL6EP expression shows unfavorable associations in THCA, UCEC, KICH, BRCA and TGCT, but favorable associations in BLCA. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for LDHAL6EP RNA expression.
This table summarizes LDHAL6EP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LDHAL6EP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LDHAL6EP shows lower tumor expression in COAD, THCA, READ and LUSC and higher tumor expression in PRAD and CHOL. The COAD box plot shows higher LDHAL6EP RNA expression in normal versus tumor tissue (log2 FC = −0.146, t-test p < 0.001).
This table shows molecular features associated with LDHAL6EP in patient tissues and cancer cell lines. In patient samples, LDHAL6EP shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
